Yahoo Web Search

Search results

1. • Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (...

     WJTV Jackson· 3 days ago

     The poster presented at ASCO 2024 will be available online in the "Publications" section of Carisma's website at https://carismatx.com/technology/publications/ following the ...

2. • Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

     Morningstar· 3 days ago

     The first presentation will feature data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma.

3. • ...-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical...

     Digital Journal· 3 days ago

     TuHURA recently announced it has entered into a definitive agreement for an all-stock transaction with Kintara Therapeutics, Inc...

4. • AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of...

     Morningstar· 3 days ago

     ROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development ...

5. • Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual...

     Benzinga· 4 days ago

     REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8

6. • ...Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20...

     ABC 26 New Orleans· 4 days ago

     ...a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases, announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)...

7. • ...COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal...

     Morningstar· 3 days ago

     HOLON, Israel, April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (

8. • 

     HOOKIPA advances HPV cancer trial with FDA nod By Investing.com

     Investing.com· 2 days ago

     HOOKIPA Pharma Inc. (NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has announced the...

9. • Lofree Launches Edge: Smoothest Ultra Low-Profile Mechanical Keyboard

     Digital Journal· 3 days ago

     ...

10. • Small Business - Cordele Dispatch | Cordele Dispatch

      Cordele Dispatch· 3 days ago

      Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation